Faeth Therapeutics Reports PIKTOR Matches or Exceeds Gedatolisib in Preclinical Breast Cancer Models

Bitget2026/10/23 13:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Faeth Therapeutics presented preclinical PIKTOR results in HR-positive, HER2-negative breast cancer models at the ESMO Congress 2026 in Madrid.
Oral PIKTOR matched or exceeded intravenous gedatolisib in suppressing tumor growth in mouse models.
Combined with fulvestrant and palbociclib, PIKTOR halted tumor growth in one model and shrank tumors in another.
The findings support the ongoing Phase 1b/2 FTH-PIK-101 breast cancer trial, with interim data expected in 2027.
Topline results from Phase 2 FTH-PIK-201 in second-line advanced endometrial cancer are expected by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023657226) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Faeth Therapeutics Reports PIKTOR Matches or Exceeds Gedatolisib in Preclinical Breast Cancer Models

You may also like

Crypto prices